The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes

Loganathan,Jagadish; Jiang,Jiahua; Smith,Amanda; Jedinak,Andrej; Thyagarajan-Sahu,Anita; Sandusky,George E.; Nakshatri,Harikrishna; Sliva,Daniel

doi:10.3892/ijo.2014.2375

The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes

Authors:
- Jagadish Loganathan
- Jiahua Jiang
- Amanda Smith
- Andrej Jedinak
- Anita Thyagarajan-Sahu
- George E. Sandusky
- Harikrishna Nakshatri
- Daniel Sliva
View Affiliations

Affiliations: Cancer Research Laboratory, Methodist Research Institute, Indiana University Health, Indianapolis, IN 46202, USA, Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Published online on: April 9, 2014 https://doi.org/10.3892/ijo.2014.2375
Pages: 2009-2015

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer metastasis is one of the major reasons for the high morbidity and mortality of breast cancer patients. In spite of surgical interventions, chemotherapy, radiation therapy and targeted therapy, some patients are considering alternative therapies with herbal/natural products. In the present study, we evaluated a well-characterized extract from the medicinal mushroom Ganoderma lucidum (GLE) for its affects on tumor growth and breast-to-lung cancer metastasis. MDA-MB-231 human breast cancer cells were implanted into the mammary fat pads of nude mice. GLE (100 mg/kg/every other day) was administered to the mice by an oral gavage for 4 weeks, and tumor size was measured using microcalipers. Lung metastases were evaluated by hematoxylin and eosin (H&E) staining. Gene expression in MDA-MB-231 cells was determined by DNA microarray analysis and confirmed by quantitative PCR. Identified genes were silenced by siRNA, and cell migration was determined in Boyden chambers and by wound-healing assay. Although an oral administration of GLE only slightly suppressed the growth of large tumors, the same treatment significantly inhibited the number of breast-to-lung cancer metastases. GLE also downregulated the expression of genes associated with invasive behavior (HRAS, VIL2, S100A4, MCAM, I2PP2A and FN1) in MDA-MB-231 cells. Gene silencing of HRAS, VIL2, S100A4, I2PP2A and FN1 by siRNA suppressed migration of MDA-MB‑231 cells. Our study suggests that an oral administration of GLE can inhibit breast-to-lung cancer metastases through the downregulation of genes responsible for cell invasiveness. The anti-metastatic benefits of GLE warrant further clinical studies.

View Figures

View References

1.	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3.	Christofori G: New signals from the invasive front. Nature. 441:444–450. 2006. View Article : Google Scholar : PubMed/NCBI
4.	Gullett NP, Ruhul Amin AR, Bayraktar S, et al: Cancer prevention with natural compounds. Semin Oncol. 37:258–281. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Zhang M, Huang J, Xie X and Holman CD: Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int J Cancer. 124:1404–1408. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Shin A, Kim J, Lim SY, Kim G, Sung MK, Lee ES and Ro J: Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr Cancer. 62:476–483. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Wasser S: Reishi or Ling Zhi (Ganoderma lucidum). Encyclopedia of Dietary Supplements. Coates PM, Blackman MR, Cragg GM, Levine M, Moss J and White JD: Marcel Dekker; New York, NY: pp. 603–622. 2005
8.	Thyagarajan A, Jiang J, Hopf A, Adamec J and Sliva D: Inhibition of oxidative stress-induced invasiveness of cancer cells by Ganoderma lucidum is mediated through the suppression of interleukin-8 secretion. Int J Mol Med. 18:657–664. 2006.PubMed/NCBI
9.	Thyagarajan A, Zhu J and Sliva D: Combined effect of green tea and Ganoderma lucidum on invasive behavior of breast cancer cells. Int J Oncol. 30:963–969. 2007.
10.	Kimura Y, Taniguchi M and Baba K: Antitumor and antimetastatic effects on liver of triterpenoid fractions of Ganoderma lucidum: mechanism of action and isolation of an active substance. Anticancer Res. 22:3309–3318. 2002.PubMed/NCBI
11.	Wang G, Zhao J, Liu J, Huang Y, Zhong JJ and Tang W: Enhancement of IL-2 and IFN-gamma expression and NK cells activity involved in the anti-tumor effect of ganoderic acid Me in vivo. Int Immunopharmacol. 7:864–870. 2007. View Article : Google Scholar : PubMed/NCBI
12.	Chen NH, Liu JW and Zhong JJ: Ganoderic acid T inhibits tumor invasion in vitro and in vivo through inhibition of MMP expression. Pharmacol Rep. 62:150–163. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Nonaka Y, Ishibashi H, Nakai M, Shibata H, Kiso Y and Abe S: Effects of the antlered form of Ganoderma lucidum on tumor growth and metastasis in cyclophosphamide-treated mice. Biosci Biotechnol Biochem. 72:1399–1408. 2008.PubMed/NCBI
14.	Weng CJ, Chau CF, Yen GC, Liao JW, Chen DH and Chen KD: Inhibitory effects of Ganoderma lucidum on tumorigenesis and metastasis of human hepatoma cells in cells and animal models. J Agric Food Chem. 57:5049–5057. 2009.
15.	Dudhgaonkar S, Thyagarajan A and Sliva D: Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol. 9:1272–1280. 2009. View Article : Google Scholar : PubMed/NCBI
16.	Sweeney CJ, Mehrotra S, Sadaria MR, et al: The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 4:1004–1012. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Sliva D, Mason R, Xiao H and English D: Enhancement of the migration of metastatic human breast cancer cells by phosphatidic acid. Biochem Biophys Res Commun. 268:471–479. 2000. View Article : Google Scholar : PubMed/NCBI
18.	Moon A, Kim MS, Kim TG, Kim SH, Kim HE, Chen YQ and Kim HR: H-ras, But not N-ras, induces an invasive phenotype in human breast epithelial cells: a role for MMP-2 in the H-ras-induced invasive phenotype. Int J Cancer. 85:176–181. 2000. View Article : Google Scholar : PubMed/NCBI
19.	Li Q, Wu M, Wang H, Xu G, et al: Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett. 261:55–63. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Wang Z and Griffin M: The role of TG2 in regulating S100A4-mediated mammary tumour cell migration. PLoS One. 8:e570172013. View Article : Google Scholar : PubMed/NCBI
21.	Wang L, Wang X, Liang Y, Diao X and Chen Q: S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-13. Acta Biochim Pol. 59:593–598. 2012.PubMed/NCBI
22.	Shih IM: The role of CD146 (Mel-CAM) in biology and pathology. J Pathol. 189:4–11. 1999. View Article : Google Scholar : PubMed/NCBI
23.	Zabouo G, Imbert AM, Jacquemier J, et al: CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines. Breast Cancer Res. 11:R12009. View Article : Google Scholar : PubMed/NCBI
24.	Zeng GF, Cai SX and Wu GJ: Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells. BMC Cancer. 11:1132011. View Article : Google Scholar : PubMed/NCBI
25.	Yeh E, Cunningham M, Arnold H, et al: A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 6:308–318. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Salas A, Ponnusamy S, Senkal CE, et al: Sphingosine kinase-1 and sphingosine-1 phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 117:5941–5952. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Saddoughi SA, Gencer S, Peterson YK, et al: Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 5:105–121. 2013. View Article : Google Scholar : PubMed/NCBI
28.	Pankov R and Yamada KM: Fibronectin at a glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
29.	Soikkeli J, Podlasz P, Yin M, et al: Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol. 177:387–403. 2010. View Article : Google Scholar : PubMed/NCBI
30.	Minn AJ, Gupta GP, Siegel PM, et al: Genes that mediate breast cancer metastasis to lung. Nature. 436:518–524. 2005. View Article : Google Scholar : PubMed/NCBI